West Pharma (WST) reported Q2 EPS of $2.48, $0.27 better than the analyst estimate of $2.21. Revenue for the quarter came in at $771.3 million versus the consensus estimate of $755.08 million.
GUIDANCE:
West Pharma sees FY2022 EPS of $9.00-$9.12, versus the consensus of $9.32.